These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 1872636)

  • 1. Vascular access thrombosis in epoetin alfa therapy.
    Leonard DK
    ANNA J; 1991 Aug; 18(4):371-6; discussion 377. PubMed ID: 1872636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [About the infrequent thrombotic events during erythropoietin therapy of anemia in ovarian cancer patients treated with chemotherapy].
    Lehoczky O; Pulay T
    Orv Hetil; 2007 Nov; 148(44):2081-5. PubMed ID: 17959551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human erythropoietin does not increase clotting in vascular accesses.
    Besarab A; Medina F; Musial E; Picarello N; Michael H
    ASAIO Trans; 1990; 36(3):M749-53. PubMed ID: 2252802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular access thrombosis in epoetin alfa therapy.
    Binkley LS
    ANNA J; 1991 Dec; 18(6):540. PubMed ID: 1750784
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
    Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
    Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis.
    Allon M; Kleinman K; Walczyk M; Kaupke C; Messer-Mann L; Olson K; Heatherington AC; Maroni BJ
    Clin Pharmacol Ther; 2002 Nov; 72(5):546-55. PubMed ID: 12426518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early surgical thrombectomy improves salvage of thrombosed vascular accesses.
    Sadaghianloo N; Jean-Baptiste E; Gaid H; Islam MS; Robino C; Declemy S; Dardik A; Hassen-Khodja R
    J Vasc Surg; 2014 May; 59(5):1377-84.e1-2. PubMed ID: 24462513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epoetin alfa: patient management issues and development through recombinant DNA technology. Part 1: Focus on Epoetin alfa patient management and recombinant DNA technology.
    Latham D; Nichols E
    ANNA J; 1990 Aug; 17(4):311-4. PubMed ID: 2396857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis.
    Więcek A; Ahmed I; Scigalla P; Koytchev R
    Adv Ther; 2010 Dec; 27(12):941-52. PubMed ID: 20972656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.
    Moran LJ; Carey P; Johnson CA
    Am J Hosp Pharm; 1992 Jun; 49(6):1451-4. PubMed ID: 1529988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis.
    Goodkin DA; Gimenez LF; Graber SE; Van Stone JC; Egrie JC; Okamoto DM
    Clin Nephrol; 1999 Jun; 51(6):367-72. PubMed ID: 10404697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epoetin delta in the management of renal anaemia: results of a 6-month study.
    Martin KJ;
    Nephrol Dial Transplant; 2007 Oct; 22(10):3052-4. PubMed ID: 17660186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arteriovenous grafts in the thigh: an excellent hemodialysis vascular access when arm vasculature is exhausted.
    Ponikvar R
    Ther Apher Dial; 2013 Aug; 17(4):416-8. PubMed ID: 23931882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience.
    Agrawal V; Mukherjee S; Kosuri R; Dumler F
    Am J Ther; 2010; 17(5):469-75. PubMed ID: 19770634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes associated with conversion from epoetin alfa to darbepoetin alfa in hospitalized hemodialysis patients.
    Sarac E; Chikyarappa A; Sabol B; Gemmel D; Globe D; Barlev A; Audhya P
    Am J Nephrol; 2006; 26(6):571-8. PubMed ID: 17170523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial.
    Keown PA; Churchill DN; Poulin-Costello M; Lei L; Gantotti S; Agodoa I; Gitlin M; Gandra SR; Mayne TJ
    Hemodial Int; 2010 Apr; 14(2):168-73. PubMed ID: 20345390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.